Role of Extracellular RNA in Atherosclerotic Plaque Formation in Mice

Sakine Simsekylmaz, PhD*; Hector A. Cabrera-Fuentes, MSc*; Svenja Meiler, PhD; Sawa Kostin, PhD, MD; Yvonne Baumer, PhD; Elisa A. Liehn, MD, PhD; Christian Weber, MD; William A. Boisvert, PhD; Klaus T. Preissner, PhD†; Alma Zernecke, MD†

Methods and Results—The presence of eRNA was revealed in atherosclerotic lesions from high-fat diet–fed low-density lipoprotein receptor–deficient (Ldlr−/−) mice in a time-progressive fashion. RNase activity in plasma increased within the first 2 weeks (44±9 versus 70±7 mU/mg protein; P=0.0012), followed by a decrease to levels below baseline after 4 weeks of high-fat diet (44±9 versus 12±2 mU/mg protein; P<0.0001). Exposure of bone marrow–derived macrophages to eRNA resulted in a concentration-dependent upregulation of the proinflammatory mediators tumor necrosis factor-α, arginase-2, interleukin-1β, interleukin-6, and interferon-γ. In a model of accelerated atherosclerosis after arterial injury in apolipoprotein E–deficient (ApoE−/−) mice, treatment with RNase1 diminished the increased plasma level of eRNA evidenced after injury. Likewise, RNase1 administration reduced neointima formation in comparison with vehicle-treated ApoE−/− controls (25.0±6.2 versus 46.9±6.9×10³ μm², P=0.0339) and was associated with a significant decrease in plaque macrophage content. Functionally, RNase1 treatment impaired monocyte arrest on activated smooth muscle cells under flow conditions in vitro and inhibited leukocyte recruitment to injured carotid arteries in vivo.

Conclusions—Because eRNA is associated with atherosclerotic lesions and contributes to inflammatory-dependent plaque progression in atherosclerosis-prone mice, its targeting with RNase1 may serve as a new treatment option against atherosclerosis. (Circulation. 2014;129:598-606.)

Key Words: atherosclerosis ■ inflammation ■ nucleic acids ■ vascular diseases
in a model of accelerated plaque formation in carotid arteries after injury in apolipoprotein E-deficient (ApoE−/−) mice.

Our new data provide strong evidence that eRNA-mediated reactions contribute to inflammation-driven processes in experimental atherosclerosis and vascular remodeling and that administration of RNase1 serves as a new intervention modality for protection from atherogenesis.

Methods

Mouse Models of Atherosclerosis and Intravitral Microscopy

Wild-type and Ldlr−/− mice (both on the C57BL/6J background, n=6 per group) were obtained from the Jackson Laboratory (Bar Harbor, ME), and ApoE−/− mice (C57BL/6J background, n=13–14 per group) from Charles River, Italy. Ldlr−/− mice were fed an atherogenic diet as described. ApoE−/− mice, placed on an atherogenic high-fat diet (HFD; 21% fat, 0.15% cholesterol) for 1 week before and up to 3 weeks after injury, were anesthetized (100 mg/kg ketamine hydrochloride/10 mg/kg xylazine IP) and subjected to wire-induced arterial injury of the common carotid artery, as described.11,12 Animals were treated intravenously with a bolus of 0.76 μg of RNase1 (in phosphate-buffered saline) or phosphate-buffered saline alone immediately before arterial injury, and they were continuously treated with RNase1 (1, 10, or 25 μg/mL) for 24 hours, followed by centrifugation and concentration of cell supernatants by using CentriTubes (Millipore, Frankfurt, Germany) with a cutoff at 10 kDa. TNF-α and IL-6 enzyme-linked immunosorbent assays were performed by using commercially available kits from eBioscience (Frankfurt, Germany). Total protein concentration was determined with the use of the BCA kit from Thermo-Fisher Scientific (Bonn, Germany). Human coronary artery SMCs (Promocell) and MonoMac6 cells were maintained, as described.11,12 MonoMac6 cell adhesion to SMCs was analyzed in parallel-wall flow chambers.11 Confluent SMCs were activated with eRNA (1, 10, or 25 μg/mL), or TNF-α (50 ng/mL) in the absence or presence of RNase1 (10 μg/mL) for 16 hours.

Viability Assay

Viability assays were performed after treating SMCs and MonoMac6 cells with RNase1 (10 μg/mL) for 30 minutes or 16 hours by the use of the fluorescent CellTiter-Blue cell viability assay (Promega, Mannheim, Germany).

Statistics

Data were analyzed by unpaired Student t tests or 1-way analysis of variance followed by Tukey or Dunnett multiple-comparison post tests (detailed in the online-only Data Supplement). Differences with P<0.05 were considered to be statistically significant.

Results

eRNA Accumulates Within Lesions Whereas Plasma RNase Activity Decreases With the Progression of Atherosclerosis

The presence of eRNA was evaluated by immunohistochemical staining in aortic root tissue from 8-week-old Ldlr−/− mice fed a high-fat diet and Ldlr−/− mice fed a HFD for 8, 12, or 36 weeks in comparison with chow-fed Bl6 wild-type mice. Although no eRNA was detected in chow-fed Bl6 or Ldlr−/− mice (RNA staining detectable in 4′,6-diamidino-2-phenylindole–positive cell nuclei only), eRNA accumulated in atherosclerotic lesions of HFD-fed Ldlr−/− mice in a time-progressive fashion (Figure 1). Quantification of eRNA showed a continuous increase in both the media and intima of Ldlr−/− mice with increasing durations of HFD feeding, whereas relative staining for eRNA increased in the media, exceeding that in the intima at early time points; eRNA was abundantly present predominantly in the intima at later time points, as reflected by an intense staining in this area (Figures 1A and 2A). After 36 weeks of HFD, eRNA was detectable not only along the luminal lining and in the vicinity of lesional MOMA-2+ macrophages (Figures 1E and 2B through 2E), but also within acellular necrotic core areas (Figures 1E and 2F through 2K).

We further assessed RNA-degrading RNase activity in plasma samples from these mice during the course of HFD...
feeding, and we observed a biphasic characteristic with a temporary increase during the first 2 weeks (44±9 versus 70±7 mU/mg protein; \( P=0.0012 \)), followed by a significant and sustained decrease to ≈20% to 40% of the activity in baseline controls, starting at 4 weeks of HFD feeding (44±9 versus 12±2 mU/mg protein; \( P<0.0001 \); Figure 2L).

These data indicate that plasma RNase activity is enhanced in early atherosclerosis, but decreases during further plaque growth, when eRNA accumulates within atherosclerotic lesions in a time-progressive manner.

eRNA Enhances Cytokine Secretion From Macrophages

Given the association of eRNA with macrophages within atherosclerotic lesions, we assessed whether eRNA induces inflammatory responses in macrophages. On 24 hours of stimulation of BMDMs with eRNA in vitro, mRNA expression of proinflammatory cytokines \( \text{Tnf-}\alpha, \text{Arg2}, \text{Il}-1\beta, \text{Il}-6, \text{Ifn-}\gamma \) was significantly upregulated in a concentration-dependent manner, whereas a reciprocal downregulation of the anti-inflammatory cytokines \( \text{Il}-10 \) and \( \text{Il}-4 \) was observed (Figure 3A). Similarly, recombinant mouse macrophage CSF–driven BMDM differentiation was skewed toward the M1-phenotype by exposure to eRNA, resulting in the overexpression of inflammatory markers such as \( \text{Tnf-}\alpha, \text{Arg2}, \text{Il}-1\beta, \text{Il}-6, \) and \( \text{Ifn-}\gamma \) together with \( \text{Il}-12 \) and inducible nitric oxide synthase (iNOS), whereas anti-inflammatory genes together with \( \text{Arg1} \) and macrophage mannose receptor-2 (\( \text{Cd206} \)) were significantly downregulated by eRNA (Figure 3B). The capacity of granulocyte macrophage CSF–driven BMDM differentiation (already representing an M1-phenotype)\(^{15,17}\) toward further M1 polarization in response to eRNA was moderate; nevertheless, a significant downregulation of M2 markers was confirmed (Figure I in the online-only Data Supplement). In accordance with our proposal, these data clearly corroborate that self-eRNA serves as a proinflammatory alarming signal.

Accordingly, the release of TNF-\(\alpha\) and IL-6 proteins into the cell supernatants was significantly increased by eRNA stimulation in a concentration-dependent manner (Figure 3C and 3D). We furthermore assessed whether these effects were mediated by eRNA-induced Toll-like receptor (TLR)–mediated signaling. Based on findings that no changes in \( \text{Stat1} \) expression were found in macrophages on stimulation with eRNA (Figure 3A and 3B, and Figure I in the online-only Data Supplement), we can conclude that eRNA does not

Figure 1. Time-progressive distribution of extracellular RNA (eRNA) in atherosclerotic lesions. The presence of eRNA in aortic root tissue from WT or \( \text{Ldlr}^{-/-} \) mice fed a chow diet for 8 weeks or from \( \text{Ldlr}^{-/-} \) mice fed a high-fat diet (HFD) for 8 (A through C), 12 (D), or 36 weeks (E), as indicated, was demonstrated by confocal microscopy with the use of an RNA-binding fluorescence dye (RNA Select, green) together with cell nuclei staining (4',6-diamidino-2-phenylindole [DAPI], blue). The right-hand panels in each line are confocal images with merged immunostaining for eRNA (green), cell nuclei (DAPI, blue), and smooth muscle actin (SMA, red). M indicates media; and N, neointima (n=6 per group).
engage in TLR-2 and TLR-4 signaling. Likewise, no alterations in the mRNA expression of the cytokines studied were observed after poly(IC) treatment (data not shown), indicating that also TLR-3 did not contribute to eRNA-mediated cytokine induction. Thus, eRNA functions as a powerful inducer of inflammatory cytokine responses in macrophages, independent of TLR-2, TLR-3, and TLR-4 signaling.

eRNA Serves as Damage Marker in Experimental Atherosclerosis

To assess the functional role of eRNA in lesion growth, a model of injury-induced, accelerated atherosclerosis was used. After injury, apolipoprotein E-deficient (ApoE−/−) mice displayed a marked increase in eRNA at 1 day and 1 week after injury (Figure 4A).

eRNA may be released from activated, damaged, or necrotic cells during injury and is composed mainly of ribosomal RNA (≈85%), transfer RNA (≈10%), and mRNA (≈5%).

We therefore determined the source of eRNA by analyzing the expression of specific mRNA species, indicative of the originating cell type. Quantitative polymerase chain reaction analysis revealed that both Cldn1 mRNA, used as a marker for endothelial cells, and acta2 mRNA as a marker for SMCs, as well, were increased in plasma at day 1 but not immediately after injury (Figure 4B). These data indicate that endothelial cells and SMCs release eRNA into the extracellular space during and after arterial injury.

Notably, eRNA was increased in supernatants of SMCs in a time-dependent manner when cells were treated with TNF-α (Figure 4C), indicating that SMCs may release eRNA also during cell activation.

Treatment of ApoE−/− Mice With RNase1 Diminishes Experimental Atherosclerosis

To investigate if eRNA directly or indirectly contributes to neointima formation after arterial injury, ApoE−/− mice fed a
HFD and treated with RNase1 or vehicle (phosphate-buffered saline) alone were subjected to wire-induced injury of the common carotid artery. RNase activity was markedly elevated in RNase1-treated mice, but not in control mice, throughout the 3-week study period (Figure II in the online-only Data Supplement). Moreover, RNase1 treatment inhibited the increase in eRNA (Figure 4A), and similarly diminished Cd31 and αSMA mRNA appearance in plasma after injury in comparison with control-treated ApoE−/− mice (Figure 4B), confirming the efficiency of the treatment.

Neointima formation was assessed at 1 and 3 weeks after injury and revealed a trend toward reduced neointima formation at 1 week after injury and a significant reduction by 47% after 3 weeks in RNase1-treated mice in comparison with controls (25.0±6.0×10³ μm², n=8 mice, versus 46.9±6.8×10³ μm², n=7 mice, P=0.0136), whereas medial areas were diminished at 1 week (32.0±1.3 versus 53.2±5.1×10³ μm², n=3 mice each, P=0.0159) but remained unaltered at 3 weeks after injury (Figure 5A). This was accompanied by a reduction in relative Mac-2+ macrophage plaque content (17.1±4.4% versus 61.2±7.6%, P<0.0001) but an increase of α-smooth muscle actin–positive SMC area at 3 weeks after injury (22.6±1.9 versus 15.4±4.2%, P=0.0339) (Figure 5B and 5C), suggesting a reduction in mononuclear cell infiltration and a more stable plaque phenotype in RNase1-treated mice.

Importantly, a significant upregulation of Tnf-α transcripts were observed at 1 day, 1 week, and 3 weeks and of Il-1β and Il-6 at 1 day after injury in comparison with carotid arteries before injury, which was significantly reduced by RNase1 treatment (Figure 6A through 6C). Moreover, the injury-induced sustained induction of the adhesion molecules Vcam-1, Icam-1, P-selectin, and Ccl2 was abrogated in RNase1-treated mice (Figure 6D through 6G). In line, immunofluorescence staining of TNF-α and intercellular adhesion molecule 1 protein in the arterial vessel wall, performed at 1 week after injury, was reduced in RNase1-treated mice (Figure 6H and 6I). These data demonstrate that the retardation in plaque growth induced by RNase1 treatment was associated with a diminished expression of inflammatory cytokines and adhesion molecules in inflamed arteries in vivo.
Figure 4. eRNA increases after vascular injury. A, The concentration of eRNA in plasma of ApoE−/− mice before injury (0 hours) and at indicated time points after arterial injury was measured in the control (filled bars) and the RNase1 treatment group (open bars). Values are expressed as mean±SEM (n=7 per group). *P<0.05, **P<0.1, ***P<0.01 vs 0 hour control, or as indicated. B, mRNA detection for Ccl2 (endothelial cells) and α-smooth muscle actin (Sma, smooth muscle cells) in plasma before injury (0 hours), at 1 hour and 1 day after injury (n=4–5 per group) was quantified by real-time PCR in the control (filled bars) and RNase1 treatment group (open bars). Values are expressed as mean±SEM (n=6 per group); *P<0.05. eRNA indicates extracellular RNA; ns, nonsignificant; PCR, polymerase chain reaction; and SEM, standard error of the mean.

Discussion

In the present study, the multifunctional eRNA/RNase system was characterized for its contribution to chronic vascular disease as it relates to the progression of atherosclerotic lesion formation in two established mouse models. Our data indicate that (1) in Ldlr−/− mice fed a HFD, eRNA accumulates in atherosclerotic plaques in a time-dependent manner, can be released from activated cells, and is increased in plasma of ApoE−/− mice after arterial injury; (2) conversely, a biphasic characteristic for plasma RNAse activity was observed with an increase soon after the initiation of HFD, and a decline to levels below baseline during progressive plaque growth.

Figure 5. RNase1 treatment of atherosclerosis-prone ApoE−/− mice protects from neointimal plaque formation. A through C, ApoE−/− mice fed a high-fat diet and treated vehicle (PBS, filled bars) or RNase1 (open bars) were subjected to wire-induced injury of the common carotid artery. Neointimal and medial areas were assessed 1 week (n=3 per group) and 3 weeks (n=7–8 per group) after injury. Values represent mean±SEM; *P<0.05. A, Representative images of pentachrome-stained sections at 3 weeks after injury are documented. Quantification of the relative content of Mac-2-positive neointimal macrophages (B) and α-SMA-positive SMCs (C), as well, are indicated in the control group (filled bars) in comparison with the RNase1 treatment group (open bars) 3 weeks after injury. Values represent mean±SEM; *P<0.05. ns indicates nonsignificant; PBS, phosphate-buffered saline; SEM, standard error of the mean; α-SMA, α-smooth muscle actin; and SMC, smooth muscle cell.
(3) eRNA induces an inflammatory gene expression in bone-marrow–derived macrophages and increases adhesion molecular expression in SMC; and (4) promotes monocyte adhesion to activated SMC in vitro and to the carotid vessel wall in vivo; (5) RNase1 administration in HFD-fed ApoE−/− mice results in significantly reduced neointimal plaque formation, monocyte recruitment, and vascular inflammation after injury. Together, these data provide strong evidence for a major role of the eRNA/RNase system in atherogenesis and establish RNase1 treatment as a potential novel therapeutic regimen.

Here, we demonstrate for the first time that eRNA accumulates within arterial lesions in the media and at later stages predominantly in the neointima in a time-dependent fashion, as documented by staining of affected vascular sites with an RNA-binding dye in HFD-fed mice, but not in controls. Furthermore, we evidenced an increased eRNA content in plasma after arterial injury in vivo. This may be attributable to the direct release of RNA from damaged tissues, because mRNA (as a portion of eRNA) originating from endothelial cells and SMCs was elevated as well. The TNF-α–induced increase in eRNA released from cultured SMCs further implied that RNA may also be released from cells in the context of inflammation and cytokine exposure after injury. Conversely, we recently demonstrated that eRNA may increase the extracellular concentration of TNF-α by promoting the liberation of transmembrane pro-TNF via the shedding TNF-α–converting enzyme,7 such that both reactions may amplify the concentration of TNF-α and other cytokines.

Although eRNA may be degraded by plasma RNases, increased levels of eRNA were similarly detected in patients with tumors, sepsis, or lung fibrosis.14,15 This led us to propose that eRNA, released under pathological conditions, may become protected against degradation by binding to proteins and phospholipids,19 or is associated with microparticles or exosomes.20 However, the biphasic change of vascular conditions in vitro in the absence (filled bar) or the presence of RNase1 (open bars). *P<0.05, **P<0.01, and ***P<0.001 versus 0 hours, or as indicated. H and I, Representative fluorescence images of TNF-α (H) and ICAM-1 (I) protein expression (green) at 1 week after injury, and together with cell nuclei staining (DAPI, blue). DAPI indicates 4′,6-diamidino-2-phenylindole; ICAM-1, intercellular adhesion molecule 1; PBS, phosphate-buffered saline; SEM, standard error of the mean; and TNF-α, tumor necrosis factor-α.

Figure 6. RNase1 treatment of atherosclerosis-prone ApoE−/− mice reduces vascular cytokine and adhesion molecule expression. A through I, ApoE−/− mice fed a high-fat diet and treated with vehicle (PBS, filled bars) or RNase1 (open bars) were subjected to wire-induced injury of the common carotid artery. Tnf-α (A), Il-1β (B), Il-6 (C), Icam-1 (D), Vcam-1 (E), P-selectin (F), and Ccl2 (G) mRNA expression were assessed at indicated time points after injury. Data are expressed as changes in the ratio between target gene expression and Gapdh mRNA. Values represent mean±SEM (n=12 per group); *P<0.05, **P<0.01, and ***P<0.001 versus 0 hours, or as indicated. H and I, Representative fluorescence images of TNF-α (H) and ICAM-1 (I) protein expression (green) at 1 week after injury, and together with cell nuclei staining (DAPI, blue). DAPI indicates 4′,6-diamidino-2-phenylindole; ICAM-1, intercellular adhesion molecule 1; PBS, phosphate-buffered saline; SEM, standard error of the mean; and TNF-α, tumor necrosis factor-α.
RNases, showing an increase early after the initiation of a HFD diet, but a decrease in the course of chronic lesion formation (observed from 4 weeks on), strongly implies a causal relationship between a dysbalance in the eRNA/RNase system and the initiation and progression of atherosclerosis. No significant changes in RNase activity were noted between wild-type, Ldlr−/− and ApoE−/− mice (not shown). However, no regulation in RNase activity was noted in ApoE−/− mice in the accelerated model of injury-induced atherosclerosis, suggesting that injury-associated factors, such as a massive release of RNA from damaged cells, may have either consumed the atherosclerosis-induced early increase in RNase activity or abrogated its induction.

In accordance with the damaging nature of eRNA, several proinflammatory cytokines (including TNF-α, IL-1β, IL-6) were upregulated in macrophages, whereas a decrease in anti-inflammatory cytokines was demonstrated. This is in line with a shift in macrophage polarization toward the M1-phenotype, and a repression of typical M-2 phenotype markers such as Arg1 or CD206, as well. No involvement of TLRs in self-eRNA–cell interactions was noted. Importantly, the indicated inflammatory cytokines were also increased in carotid arteries after injury in vivo, whereas RNase1 treatment significantly reduced their expression levels in comparison with controls. In essence, the appearance of eRNA in the diseased tissue may thus be considered as an alarm signal that amplifies tissue inflammation by the induction of cytokine production, and the latter process may involve the proinflammatory mediator TNF-α–converting enzyme by eRNA, as previously demonstrated by our group.21

Recently, it was revealed that eRNA not only promotes the adhesion and transmigration of leukocytes in the murine cremaster muscle vasculature, but that it also induces the expression of intercellular adhesion molecule 1 in endothelial cells in vitro.7 Similarly, we here observed an increase in adhesion molecules intercellular adhesion molecule 1, vascular cell adhesion molecule 1, P-selectin, and CCL2 in SMC, which may likewise contribute to monocyte adhesion to activated SMCs and to leukocyte recruitment in carotid arteries after injury, as well.22 Importantly, and in line with the proinflammatory function of eRNA, our findings show that the systemic treatment with RNase1 reduced adhesion molecule expression, inhibited leukocyte adhesion, and reduced arterial macrophage accumulation and neo-intimal plaque formation after injury in carotid arteries of ApoE−/− mice in vivo.

eRNA was also demonstrated to mediate vascular permeability via the mobilization/stabilization and direct binding to vascular endothelial growth factor.4 Enhanced vascular endothelial growth factor signaling induced by eRNA may, in addition, promote monocyte adhesion and plaque expansion.23

In addition, eRNA was shown to act as a prothrombotic cofactor. Accordingly, systemic treatment with RNase1 rescued mice from thrombotic occlusion of the carotid artery in a model of arterial thrombosis and reduced cerebral edema and infarction size in acute stroke.7 Neointimal hyperplasia after arterial injury is characterized by endothelial denudation, exposure of extracellular matrix, and adhesion of activated platelets, which all contribute to inflammatory leukocyte recruitment and neointima formation after injury.24 By contributing to platelet accumulation at the site of injury, eRNA may thus, in addition, promote injury-induced leukocyte adhesion and neointimal hyperplasia.

The underlying pathogenetic mechanisms of eRNA as a proinflammatory mediator may thus involve both direct and indirect signaling pathways. Our findings thus indicate that eRNA serves as an important inflammatory mediator after vascular injury, identifying extracellular ribonucleic acids as a new target for the treatment of inflammation during vascular remodeling.

The present study provides novel experimental evidence for the multifunctional properties of self-eRNA as an important trigger of different inflammatory processes that fuel atherogenesis and may culminate in atherosclerotic lesion growth. Our experimental data show that administration of RNase1 abrogates the detrimental functions of eRNA, and provide promising evidence for the establishment of novel interventional strategies for the therapy of cardiovascular diseases.

Acknowledgments
We thank Stephanie Elbin, Melanie Garbe, Roya Soltan, and Sara McCurdy for excellent technical assistance and Dr Mona Saffarzadeh for helpful discussions.

Sources of Funding
This work was supported in part by the Deutsche Forschungsgemeinschaft: FOR809, ZE-827/1-2, ZE-827/4-1 and SFB688 TPA12 to Dr Zernecke; PROMISE-IRTG-1566 and the Excellence Cluster Cardiopulmonary System to Dr Preissner; National Institutes of Health grants HL75677 and HL081863, and Hawaii Community Foundation grant 47037 to Dr Boisvert. Core facilities at the University of Hawaii were supported by P30GM103341. We are grateful for the support of a stipend (laboratory-rotation fellowship) from the “International Giessen-Graduate Center for the Life Sciences” (GGL) and by the Giessen-Kazan Partnership (Deutscher Akademischer Austauschdienst; DAAD; Bonn, Germany) to Cabrera-Fuentes.

Disclosures
None.

References

**CLINICAL PERSPECTIVE**

Atherosclerosis remains the number one cause of death in the Western world, and the therapeutic options currently available are limited. Regarded as a chronic inflammatory disease of the vessel wall, monocytes/macrophages, inflamed smooth muscle cells, and several cytokines, proteases, and other molecular players, as well, contribute to disease development. Based on our previous studies concerning extracellular RNA (eRNA) as a novel alarm signal and potent cofactor in inflammation and thrombosis, we here investigated the contribution of the eRNA/RNase system during atherogenesis. In the experimental model of high-fat diet–induced atherosclerosis in low-density lipoprotein receptor–deficient and apolipoprotein E–deficient mice, eRNA accumulated in atherosclerotic plaques in a time-dependent manner, but was also released from activated cells, yielding increased plasma levels after arterial injury. In fact, eRNA functioned to promote inflammatory gene expression in macrophages and smooth muscle cells. Importantly, eRNA-degrading RNase1, administered via minipumps, significantly reduced plaque formation, monocyte recruitment, and vascular inflammation after injury. These data provide evidence for a major role of the eRNA/RNase system in atherogenesis and identify eRNA as an important trigger of inflammatory processes that fuel atherosclerotic lesion growth. These novel data extend our previous findings in which RNase1 was found to reduce infarction size in acute stroke. Thus, our study may harbor great potential for the establishment of RNase1 administration as a novel interventional strategy for the therapy of cardiovascular diseases. Because RNase1 is a thermostable, non-toxic enzyme, it bears several features that are applicable as a new interventional regimen against atherothrombotic disease.
Role of Extracellular RNA in Atherosclerotic Plaque Formation in Mice

Sakine Simsekyilmaz, Hector A. Cabrera-Fuentes, Svenja Meiler, Sawa Kostin, Yvonne Baumer, Elisa A. Liehn, Christian Weber, William A. Boisvert, Klaus T. Preissner and Alma Zernecke

Circulation. 2014;129:598-606; originally published online November 7, 2013; doi: 10.1161/CIRCULATIONAHA.113.002562

Circulation is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2013 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/129/5/598

Data Supplement (unedited) at:
http://circ.ahajournals.org/content/suppl/2013/11/07/CIRCULATIONAHA.113.002562.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation is online at:
http://circ.ahajournals.org/subscriptions/
Supplemental Methods

Arterial wire-induced injury
Wild-type and Ldlr/− mice (both on the C57BL/6J background) were obtained from the Jackson Laboratory (Bar Harbor, ME, USA), and apoE/− mice (C57BL/6J background) from Charles River, Italy. At 6 to 8 weeks of age mice were placed on an atherogenic diet (21% fat, 0.15% cholesterol, Altromin) for one week before and up to three weeks after injury. Animals were treated intravenously with a bolus of 0.76 µg RNase1 (in PBS) or PBS alone immediately before wire-induced injury and continuously treated with RNase1 via Alzet® osmotic minipumps (42 µg/kg mouse per day), subcutaneously implanted one day before injury. For induction of wire-induced injury, mice were anesthetised intraperitoneally with ketamine and xylazine. After midline neck incision, the left external carotid artery was tied off distally, and via transverse arteriotomy, a 0.014-in flexible angioplasty guidewire was advanced by 1 cm. Complete and uniform endothelial denudation was achieved by 3 passes along the common carotid artery with a rotating motion. All animal studies were approved by local authorities and complied with German animal protection law.

High-fat-diet driven atherosclerosis in LDL-receptor-deficient mice
C57BL/6J and Ldlr/− mice (C57BL/6J background) were obtained from Jackson Laboratory and were fed with atherogenic diet as described1.

Immunohistochemistry
For evaluation of neointima formation, mice were sacrificed at indicated time points, in situ fixed with 4 % paraformaldehyde, and carotid arteries were excised and embedded in paraffin. Neointimal and medial areas were quantified in serial sections (5 µm; 10 per mouse) within 500 µm from the bifurcation by Movat’s pentachrome staining and planimetry of the areas within external elastic lamina, internal elastic lamina, or lumen (Diskus software, Hilgers). Adjacent sections were used to assess plaque cellular content by immunofluorescence staining of macrophages and SMCs by mAb staining for Mac2 (rat anti-mouse, Santa Cruz) and α-smooth muscle actin (mouse anti-human, Santa Cruz), respectively. Briefly, slides were blocked with 1% bovine serum albumin (Sigma Aldrich), incubated with primary antibody overnight at 4°C, and secondary detection performed using the relevant Alexafluor 488-conjugated antibody (Molecular Probes, Life Technologies, Germany). Sections were
counterstained with DAPI (1µg/mL; Merck, Darmstadt Germany) for visualisation of cell nuclei, then coverslipped using Vectorshield mounting medium (Vector Laboratories, Burlingame, USA). Images were recorded using a Leica DM-RXE fluorescence microscope, and quantified using Diskus software.

To determine the distribution of eRNA in atherosclerotic lesions, mice were sacrificed at indicated time points and perfused via the left ventricle with 10 ml PBS containing 1 mM EDTA and 30 ml fixative (PBS, 4% paraformaldehyde and 5% sucrose), and the atherosclerotic lesions were analyzed in the heart aortic valve as described previously1. Immunohistochemistry was performed on 5 µm cryostat tissue sections, fixed for 15 min in acetone at -20°C. SYTO® RNASelect™ dye (Invitrogen, USA) and the primary antibody recognizing rat anti-mouse MOMA-2 monoclonal antibody (Abcam, Cambridge, UK) against monocytes/macrophages were incubated for 1 h at room temperature followed by a secondary antibody conjugated with Cy3 (Abcam), or primary antibody against TNF-α (goat anti-mouse polyclonal, Santa Cruz) or Icam-1 (rat anti-mouse monoclonal, ebioscience), detected by FITC-konjugated secondary antibody (rabbit anti-goat IgG, goat anti-rat IgG, Jackson ImmunoResearch). Tissue sections were counterstained with DAPI (1µg/ml, Sigma Aldrich) for nuclei detection. Specimens were visualized using the confocal NIKON-microscope ECLIPSE TE200-E (Nikon, Düsseldorf, Germany), sections were taken through the tissue at 0.25 µm intervals, and analyzed by image acquisition software EZ-C1 Goldversion 3.8.

Confocal microscopy and quantification of RNA
Cryosections (5 µm thick) of aortic sinus from Ldlr<sup>−/−</sup> mice were air dried and fixed with 4% paraformaldehyde and then incubated with 1% bovine serum albumin for 30 min to block non-specific binding sites. After rinsing in PBS, the samples were incubated 2 h at room temperature with primary antibodies against smooth muscle α-actin TRITC-labeled (Sigma). After repeated washes with PBS, the tissue sections were incubated with SYTO® RNAsSelect™ dye (Invitrogen) used for RNA localization. Nuclei were visualized with DAPI (Molecular Probes). Tissue sections were examined by laser scanning confocal microscopy (Leica TCS SP2), and confocal optical sections were taken using a Leica x63/1.32 objective lens. Each recorded image was taken using multi-channel scanning and consisted of 1024 x 1024 pixels. To improve image quality and to obtain a high signal to noise ratio, each image from the series was signal-averaged and was deconvoluted using AutoQuant X2 software (Bitplane, Zürich, Switzerland). For three-dimensional image reconstructions, an Imaris 6.3.1 multichannel image processing software (Bitplane) was used.
For quantification of the eRNA, all tissue samples were simultaneously immunolabeled under identical conditions of fixation and dilutions of primary and secondary antibodies. Ten randomly chosen fields of vision were quantified using three-dimensional “Quantification“ and “VoxelShop“ options of Imaris 6.3.1 (Bitplane). The area of specific labeling for eRNA was calculated as arbitrary fluorescent units of positive labelling, each for the media area or neointima area, as previously described.²

**Intravital imaging**

For intravital microscopy, 0.05% rhodamine-G (Molecular Probes) was administered i.v. to apoE−/− mice fed an atherogenic diet and treated with RNase or vehicle (PBS) 1 day after injury. Carotid arteries were exposed in anesthetized mice (100 mg/kg bodyweight ketamine and 10 mg/kg bodyweight xylazine). Arrest of labeled leukocytes was visualized by epifluorescence microscopy (Olympus BX51, 20x water immersion), and recorded using a digital camera (Hamamatsu EM-CCD, C9100) and analysed using Cell-R software (Olympus).

**Isolation of extracellular RNA and real time PCR analysis**

DNA-free total RNA was extracted from plasma of mice or, from supernatants of SMC or SMC using Zymo RNA MicroPrep kit (Zymo Research) omitting a lysis step and with an additional DNase digestion step. Total RNA (10 ng) was reverse-transcribed at 37°C for 1 h. cDNA fragments were amplified by 45 cycles of PCR (denaturing at 95°C for 15 s, annealing at 58°C for 30 s, and extension at 72°C for 30 s); the last extension was performed at 50°C for 2 min. The following primers were used:

- **Mouse Cd31** forward 5’-CTCCAACAGAGCCAGCAGTA-3’,
- **mouse Cd31** reverse 5’-GACCACCTCAATGACAAACA-3’,
- **mouse Sma** forward 5’-CTGACAGAGGCACCATGAA-3’,
- **mouse Sma** reverse 5’-AGAGGCATAGAGGGACAGCA-3’,
- **mouse Gapdh** forward 5’-CCTCAAGATTGTCAGC-3’,
- **mouse Gapdh** reverse 5’-CCACAGCCTTGGCAGC-3’,
- **mouse Icam-1** forward 5’-GCCTTGGTAGAGGTGACTGAG-3’,
- **mouse Icam-1** reverse 5’-GACCGGAGCTGAAAAGTTGTA-3’,
- **mouse Vcam-1** forward 5’-TGCCGAGCTAAATTACACATTG-3’,
- **mouse Vcam-1** reverse 5’-CCTTGTGGAGGGATGTACAGA-3’,
- **mouse P-selectin** forward 5’-AGGGAAATGATGCCATTCAG-3’,
- **mouse P-selectin** reverse 5’-ACCGGAAACTCTGGACATTG-3’
mouse Ccl2 forward 5’-GATGCAGTTAACGCCACT-3’
mouse Ccl2 reverse 5’-AGCTTCTTTGGGACACCTGC-3’
mouse Tnf-α forward 5’-ACTGAACCTCGGGGTGATCG-3’
mouse Tnf-α reverse 5’-GGCTACAGGCTTGTCACTGC-3’
mouse Il-1β forward 5’-GGATGAGGACATGAGCATCT-3’
mouse Il-1β reverse 5’-GGAGCGCTGTAGTGCACTTG-3’
mouse Il-6 forward 5’-ATGGATGCTACCAACTTGGAAT-3’
mouse Il-6 reverse 5’-TGAAGGAGCTCTGGCTTTG-3’

After incubation with or without eRNA (1 - 25 µg/ml), total cellular RNA was extracted from BMDM using TRIzol® Reagent (Invitrogen, USA). RNA samples were then subjected to RNA purification using the RNeasy minikit (Qiagen, USA). One µg of DNase-treated total RNA was reverse-transcribed using GoScript™ Reverse Transcription System (Promega, USA). Real-time quantitative RT-PCR (q-PCR) was performed at Genomics Core Facility, John A. Burns School of Medicine, Hawaii. The gene products were quantified using SYBR Green assays (Applied Biosystems). mRNA signal from GAPDH was used for normalization. The 50 pmol of each primer was used with the following sequences:
Mouse Gapdh forward 5’-GGCAAATTCAACGGCACAG-3’,
mouse Gapdh reverse 5’-CGCTCCTGGAGATGCTGA-3’,
mouse Il-1β forward 5’-GGGCCTCAAGGAAAAGAATC-3’,
mouse Il-1β reverse 5’-TTCTCCTTGAGAGGTGCTCA-3’,
mouse Tnf-α forward 5’-CATCTTCTCAAAATTCGAGAGGACATGACAA-3’,
mouse Tnf-α reverse 5’-TGGGAGTAGACAAGGTGAGGTACAC-3’,
mouse Il-6 forward 5’-GAGGATCACCCTCAACAGACCC-3’,
mouse Il-6 reverse 5’-AAGTGCACTCTGTTGTCATACA-3’,
mouse Inf-γ forward 5’-TGGACTGCTGAGATTTTTCAT-3’,
mouse Inf-γ reverse 5’-TCAAGTGGCATTAGATGTCGA-3’,
mouse Il-10 forward 5’-TGACTACCAAAGGCAACAGGTC-3’,
mouse Il-10 reverse 5’-TGGGAAGTGGGTGCATTATTG-3’,
mouse Il-4 forward 5’-CAACGAAGAACACCACAGGAC-3’,
mouse Il-4 reverse 5’-AAGTGCACTCTGTTGTCATACA-3’,
mouse Arg2 forward 5’-CCTCCCTGCAATCATGCTTC-3’,
mouse Arg2 reverse 5’-CCTCCTGCAATCATGCTTC-3’,
mouse Il-12 forward 5’-CCCTGTGCTTTGTAAGTCAT-3’,
mouse *Il-12* reverse 3’-CTGAAGTGCTGCCTTGATGG-3’,
mouse *iNOS* forward 5’-CTCTGGTCTTGCAAGCTGATGGTCA-3’,
mouse *iNOS* reverse 5’- TCCTGGAACCACCTCGTACTTGGGAT-3’,

**Cell culture and cell adhesion assay under flow**

Human coronary artery SMC (Promocell) and MonoMac6 cells were maintained as described³, ⁴. MonoMac6 cell adhesion to SMC was analyzed in parallel wall flow-chambers³. Confluent SMC were activated with TNF-α (50 ng/ml) in the absence or presence of RNase1 (10 µg/ml) for 16 h. Likewise, MonoMac6 cells were left untreated or pretreated with RNase1 (10 µg/ml) for 16 h and suspended (at 1x10⁶ cells/ml) in HH-medium (1x Hank’s buffered saline solution, containing 10 µM HEPES and 5 mg/ml bovine serum albumin). Confluent SMC were activated with TNF-α (50 ng/ml) followed by treatment with buffer alone or RNase1 (10 µg/ml) for 16 h. Prior to the experiment, CaCl₂ and MgCl₂ (each at 1 mM) were added to MonoMac6 cells, which were perfused over SMC at 1.5 dyne/cm². After 5 min, firm adherence of cells was assessed by phase-contrast video microscopy and quantified in multiple fields recorded with a JVC 3CCD video camera.

**Viability assay**

After treating SMC or MM6 with RNase1 (10 µg/ml) for 30 min or 16 h, respectively, viability assays were performed by using the fluorescent CellTiter-Blue® cell viability assay (Promega) according to the manufacturer’s instructions.

**Statistics**

Data were analyzed by unpaired Student t tests, and if more than 2 groups were compared by ANOVA 1-way analysis of variance followed by Tukey's or Dunnett’s multiple comparison post tests. Differences with *p*<0.05 were considered to be statistically significant. Analyses for Figures 5A-C, and Figure 7B were performed using two tailed t-tests. Analyses for Figure 2L and 4A were performed using a one-way ANOVA followed by Tukey multiple comparison test. Analysis for Figure 2A, 3A-D, 4B-C, 6A-G, 7B and Supplemental Figure 1 and 3 were performed using a one-way ANOVA followed by Dunnett’s multiple comparison test. Statistical analyses were performed using Graph Pad Prism 6.0.
Supplemental Figures

Supplemental Figure 1

Supplemental Figure 1. mRNA expression of *Tnf-α*, *Arg2*, *Il-1β*, *Il-6*, *Il-12*, *iNOS*, *Ifn-γ*, *Il-10*, *Il-4*, *Stat1*, *Cd206* and *Arg1* in wild-type BMDM, differentiated in the presence of mouse recombinant GM-CSF was analyzed by real-time PCR in the absence (control, dotted line) or presence of eRNA (1, 10, or 25 μg/ml) for 24 h. Data are expressed as changes in the ratio between target gene expression and *Gapdh* mRNA. Values represent mean ± SD (n=6 per group); *p<0.05, **p<0.01, ***p<0.001 vs. control, ns = non-significant.
**Supplemental Figure 2.** RNase activity in plasma of apoE<sup>-/-</sup> mice at indicated time points after arterial injury in the control and the RNase1 treatment group (n=4 per group). Values represent mean ± SEM.
Supplemental Figure 3

Supplemental Figure 3. mRNA expression of Icam1, Vcam1, P-selectin and Ccl2 in SMC was analyzed by real-time PCR in the absence or presence of eRNA (1, 10, or 25 μg/ml) after 16 hours (n=9 per group). Values represent mean ± SEM; *p<0.05, **p<0.01 vs. unstimulated controls.
Supplemental References


